All In Biotech

Drug Trial Radar · NCT07140211

Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis

Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis: a Pragmatic, Multi-center, Open-label Randomized Controlled Study

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 9,200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

9,200

Planned (sponsor's estimate)

Start

Oct 15, 2025

Primary completion

Aug 2030

Study completion Aug 2030

Sponsor

Lead sponsor
Marc BlondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the risk-benefit of a short-term treatment with a low-dose low-molecular-weight heparin (LMWH), in the postpartum period (after delivery). The main questions it aims to answer are: * compared to no treatment, does short-term postpartum LMWH modify the risk of venous thromboembolism within 90 days of delivery? * compared to no treatment, does short-term postpartum LMWH modify the risks of bleeding and wound complications? Participants will take low-dose LMWH for 7-10 days or no treatment, and will be followed for 90 days post-delivery.

Conditions

  • Venous Thromboembolism (VTE)
  • Postpartum

Interventions

  • Low-dose low-molecular-weight heparinDrug

    Low-molecular-weight heparin given for 7-10 days after delivery: * enoxaparin 4000-6000IU o.d. * nadroparin 3800-5700IU o.d. * dalteparin 5000-7500IU o.d. * tinzaparin 4500-7000IU o.d.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Venous thrombotic outcomesTime frame: Within 90 days post-randomization

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Kantonsspital Baden

    Baden, Switzerland · Recruiting

  • Universitätsspital Basel

    Basel, Switzerland · Recruiting

  • Lindenhofspital

    Bern, Switzerland · Recruiting

  • Geneva University Hospitals

    Geneva, Switzerland · Recruiting

  • Centre Hospitalier Universitaire Vaudois

    Lausanne, Switzerland · Recruiting

  • Luzerner Kantonspital

    Lucerne, Switzerland · Recruiting

  • Ente Ospedaliero Cantonale

    Lugano, Switzerland · Recruiting

  • Réseau Hospitalier Neuchâtelois

    Neuchâtel, Switzerland · Recruiting

  • Hôpital du Valais

    Sion, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.